Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the situations in which measurable residual disease (MRD) should and should not be used to define the success of therapy. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
When is the use of MRD appropriate?
